DK148751B - Fremgangsmaade til fremstilling af cyclosporinderivater - Google Patents

Fremgangsmaade til fremstilling af cyclosporinderivater Download PDF

Info

Publication number
DK148751B
DK148751B DK188778AA DK188778A DK148751B DK 148751 B DK148751 B DK 148751B DK 188778A A DK188778A A DK 188778AA DK 188778 A DK188778 A DK 188778A DK 148751 B DK148751 B DK 148751B
Authority
DK
Denmark
Prior art keywords
cyclosporin
isocyclosporin
evaporated
hereinafter
vacuo
Prior art date
Application number
DK188778AA
Other languages
English (en)
Other versions
DK148751C (da
DK188778A (da
Inventor
Rene P Traber
Max Kuhn
Hans Hofmann
Eugen Haerri
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH582377A external-priority patent/CH628023A5/de
Priority claimed from CH582277A external-priority patent/CH628022A5/de
Priority claimed from CH745777A external-priority patent/CH632010A5/de
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of DK188778A publication Critical patent/DK188778A/da
Publication of DK148751B publication Critical patent/DK148751B/da
Application granted granted Critical
Publication of DK148751C publication Critical patent/DK148751C/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/911Microorganisms using fungi
    • Y10S435/945Trichoderma
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/19Antibiotic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/27Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Description

i 148751
Den foreliggende opfindelse angår en fremgangsmåde til fremstilling af hidtil ukendte cyclosporinderivater med den almene formel I
CH3v /H3 CH C?3 /CH3 CH, CH, I Nh \V 3 CH, CH,I CH ,3 I 2 I 3I il CH,-N-CH-CO-N — CH- A — CO-N-CH-C-N-CH, 3 L L I L II I 2
„„CO H O CO
I I I
CH-CH,-CH l n-ch, 1 CH3/ 2 I 3
Η O H
I D L I L || L I L
OC-CH-N-CO-CH-N-CO-CH-N-C-CH-N-CO-CH
111 111 I
CH, H CH, CH, CH, CH CH, 3 3 .*2 V\ I 2
CH CH3 CH3 CH
ch3 nch3 ch3 ch3 hvor A betegner
CH, H
\y c 5 (i det nedenstående / \
H CH
betegnet cyclosporin D), i 2
e,,er HO _ CH
^cif ^CH,
f3 I
-C-N-CH —
II L
O
2 148751 CH3\ CH, I 2 H2C\
CH
I 2
IR
(i det nedenstående HØ ^
betegnet dihydro-cyclo- ^CH
sporin D), eller CH^ j 3 | N lH~ 0
CH, H
\ /
C
H CH,
(i det nedenstående |R
5 betegnet isocyclosporin D). 0 n CH
κ\κ/ \ XCH CH,
-C HN-CH
I 1 L
b ch3
Det er kendt, jfr. dansk fremlæggelsesskrift nr. 136.780 og beskrivelsen til dansk patentansøgning nr. 4831/76, at fremstille antibiotika betegnet cyclosporin A (også kendt som S 7481/F-1), cyclosporin B
3 148751 (også kendt som S 7481/F-2) og cyclosporin C ved dyrkning af en stamme af svampearten Trichoderma polysporum (Link ex. Pers) især NRRL 8044 og isolering af nævnte cyclosporiner fra kulturfiltratet.
Nævnte stamme indordnes nu under svampearten Tolypocladium infla-5 turn Cams. Cyclosporin A, B og C har immunoundertrykkende, betændelseshæmmende og arthritishæmmende virkning.
Det har nu overraskende vist sig, at ovennævnte svampeart ud over cyclosporin A, B og C danner en yderligere cyclosporin, nemlig cyclosporin D.
10 Fremgangsmåden ifølge den foreliggende opfindelse til fremstilling af de hidtil ukendte cyclosporin D, dihydro-cyclosporin D eller isocyclo-sporin D er i overensstemmelse hermed ejendommelig ved, at a) der ud fra et kulturfiltrat vundet ved dyrkning af en cyclospo-rin-producerende stamme af svampearten Tolypocladium inflatum Cams
15 isoleres cyclosporin D, hvorpå det vundne cyclosporin D
b) eventuelt hydrogeneres til dannelse af dihydro-cyclosporin D, eller c) eventuelt underkastes syrebehandling til dannelse af isocyclosporin D.
Til fremstillingen af cyclosporin D kan som nævnt anvendes stammer 20 af svampearten Tolypocladium inflatum Cams, fx NRRL 8044 eller sådanne, som kan fås ved selektion eller mutation af svampestammen NRRL 8044 ved påvirkning med ultraviolette stråler eller røntgenstråler eller under anvendelse af andre foranstaltninger, fx behandling af laboratoriekulturer med egnede kemikalier. 1
Cyclosporin D kan isoleres på i og for sig kendt måde, fx som beskrevet i eksempel 1. Herved kan cyclosporin D skilles fra samtidigt i store mængder tilstedeværende noget mere polært cyclosporin A, mere polært cyclosporin B og det endnu mere polære cyclosporin C.
4 148751
Det eventuelle fremgangsmådetrin b) ifølge den foreliggende opfindelse kan udføres på i og for sig kendte måder, fx ved katalytisk hydrogenering.
Som opløsningsmidler kan fortrinsvis anvendes lavere aliphatiske alko-5 holer, fx methanol, ethanol eller isopropanol, eller ethylacetat. Hydrogeneringen udføres hensigtsmæssigt ved neutral pH-værdi ved temperaturer mellem 20 og 30°C og ved atmosfæretryk eller ved svagt forhøjet tryk. Som katalysator anvendes fortrinsvis palladium, fx palladium/kul.
10 Syrebehandlingen ved det eventuelle fremgangsmådetrin c) kan udføres på i og for sig kendt måde, fx med trifluoreddikesyre, fortrinsvis med methansulfonsyre eller p-toluensulfonsyre.
Den til isomeriseringen anvendte mængde stærk syre ligger fortrinsvis mellem 1 og 4 mol pr. mol cyclosporin D.
15 Som opløsningsmidler kan fx anvendes lavere alkoholer, fx methanol, halogenerede carbonhydrider, fx chloroform, eller ethere, fx dioxan.
Reaktionstemperaturen kan variere mellem 20 og 65°C, fortrinsvis mellem 45 og 55°C.
Cyclosporin D, dihydro-cyclosporin D og isocyclosporin D udmærker 20 sig ved interessante kemoterapeutiske og farmakologiske egenskaber og kan derfor anvendes som lægemidler.
Cyclosporin D, dihydro-cyc.losporin D og isocyclosporin D er især indiceret ti| anvendelse som antiarthritica.
Cyclosporin D, dihydro-cyclosporin D og isocyclosporin D kan som 25 lægemidler administreres alene eller i en egnet lægemiddelform sammen med farmakologisk indifferente hjælpestoffer.
Fremgangsmåden ifølge den foreliggende opfindelse belyses nærmere ved følgende eksempler.
5 148751
EKSEMPEL 1 Cyclosporin D
500 liter af en næringsopløsning, som pr. liter indeholder 40 g glucose, 2,0 g natriumcaseinat, 2,5 g ammoniumphosphat, 5 g 5 MgSO^.THjO, 2 g KHjPO^, 3 g natriumnitrat, 0,5 g kaliumchlorid, 0,01 g FeSO^ og demineraliseret vand, podes med 50 liter af en forkultur af stamme NRRL 8044 og inkuberes i 13 dage ved 27°C i en stålfermenteringsbeholder under omrøring (170 OPM) og beluftning (1 liter luft/minut/liter næringsopløsning) (se tysk offentliggørelsesskrift 10 nr. 2.455.859).
Dyrkningsvæsken ekstraheres med en lige så stor mængde n-butylace-tat, den organiske fase skilles fra og inddampes i vakuum, og råekstrakten affedtes ved tre-trins-fordeling mellem methanol-vand (9:1) og petroleumsether. Den methanoliske fase fraskilles og inddampes i 15 vakuum, og råproduktet udfældes ved tilsætning af vand. Det ved filtrering vundne materiale chromatograferes på silicagel med hexan-acetone (2:1) som elueringsmiddel, hvorhos de først eluerede fraktioner overvejende indeholder cyclosporin A og cyclosporin D og de senere eluerede dele overvejende cyclosporin C. De cyclosporin A- og 20 D-holdige fraktioner krystalliseres til yderligere rensning af en 2 til 2,5 gange så stor mængde acetone ved -15°C, og det krystallinske materiale opspaltes derpå yderligere ved to gange chromatografi på silicagel, hvorhos de med vandmættet ethylacetat først eluerede fraktioner indeholder cyclosporin D i stærkt opkoncentreret form. Disse 25 opløses i en dobbelt så stor mængde acetone og lades krystallisere ved -15°C. Det således vundne rå krystallinske cyclosporin D opløses til videre rensning i en 10 gange så stor mængde acetone, der tilsættes 2 vægtprocent aktivt kul og opvarmes i 5 minutter til 60°C. Efter filtrering over talkum fås et klart og næsten farveløst filtrat, som 30 derpå inddampes til 1/3 af det oprindelige volumen og lades afkøle til stuetemperatur, hvorved cyclosporin D spontant udkrystalliserer. Ved henstand ved -17°C fuldendes krystalliseringen. Krystallerne frafil-treres og vaskes med lidt iskold acetone og tørres derpå i højvakuum ved 80°C i 2 timer.
20 148751 6
Karakterisering af cyclosporin D:
Farveløse, prismatiske krystaller, smeltepunkt 148-151°C, [ct]^ = -245° (c = 0,52 I chloroform), [α]ρ0 = -211° (c = 0,51 i methanol).
5 EKSEMPEL 2
Dihydro-cyclosporin D
400 mg palladium/kul (10%'s palladium) forhydrogeneres i 15 ml ethanol i 20 minutter. Til denne suspension af palladiumkatalysatoren sættes en opløsning af 3,66 g cyclosporin D opnået som i eksempel 1 i 30 ml 10 ethanol, og derpå hydrogeneres ved 24°C og et tryk på 736 mm Hg, til der ikke længere optages hydrogen. Derpå filtreres katalysatoren fra, og filtratet inddampes til tørhed i vakuum ved 20-30°C. Derved fås tyndtlagschromatografisk ensartet dihydro-cyclosporin D i form af et farveløst amorft pulver, som tørres i højvakuum i 4 timer ved 15 70°C.
Egenskaber for dihydro-cyclosporin D:
Smeltepunkt 153-156°C, [a]*° = -237° (c = 0,56 i CHCIg), [,«]q° = “196° (c = 0,58 i CHgOH).
20 EKSEMPEL 3
Isocyclosporin D
Til en opløsning af 18,25 g cyclosporin D opnået som i eksempel 1 i 120 ml absolut dioxan sættes en opløsning af 3,60 g methansulfonsyre i 60 ml dioxan, og blandingen holdes ved 50°C under fugtighedsude-25 lukkelse. Reaktionens forløb følges på tyndtlagschromatogram (Poly-

Claims (6)

148751 gram SIL G-folier, chloroform-methanol-iseddike (90:6:4), ioddamp til fremkaldelse). Efter 17 timer afkøles til stuetemperatur. Syren neutraliseres ved tilsætning af 3,38 g vandfrit natriumacetat, der omrøres i 15 minutter, 5 det udfældede salt isoleres ved sugefiltrering, og filtratet inddampes i vakuum ved 45°C. Remanensen (21 g) chromatograferes på 1,5 kg si-licagel, hvorhos der elueres med chloroform-methanol (98:2). De fraktioner, som praktisk taget består af rent isocyclosporin D, forenes og inddampes i vakuum ved 50°C, og remanensen krystalliseres to til tre 10 gange af ether, hvorved fås isocyclosporin D. Egenskaber for isocyclosporin D: Farveløse prismer, smeltepunkt 142-144°C. [o]p° = -205,5° (c = 0,51 i CHCIg), [a]p° = -144,4° (c = 0,64 i CHgOH).
15 PATENTKRAV Fremgangsmåde til fremstilling af cyclosporinderivater med den almene formel I CH3 /CH3 ''cH /CH3 CH-. CH3 I CH \V 3h |H2 ?H3| T I 3 CH,-N-CH-C0-N — CH- A — CO-N-CH-C-N-CH,
3. L I 1 li I 2 CO H O CO 3\ I I . CH-CH0-CH L N-CH, 1
2 I 3 CH3-·? Η O H i D L I L || L I L OC-CH-N-CO-CH-N-CO-CII-N-C-CH-N-CO-CH III III i CHj H CH3 CH2 CH3/CH CH2 CH CH3 CH3 CH CH3 Nch3 CH3 CH3 148751 hvor A betegner CH- H \/ C A |r2 . HO CH (i det nedenstående \ηχί CH betegnet cyclosporin D), CH_ I J I J d,er -C-N- CH —
11 L o CH3\ CH, 5 (i det nedenstående CH betegnet dihydro-cyclo- i 2 sporin D), eller H0 in \ R X \ ^CH CH- CH- I i3 I -C—N-CH- II o CH, H N / C II X\ H CH, I £ i R (i det nedenstående J,u κο η ^CH <;H -C HN-CH- t 1 L
0 CH3
DK188778A 1977-05-10 1978-05-01 Fremgangsmaade til fremstilling af cyclosporinderivater DK148751C (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH582377A CH628023A5 (en) 1977-05-10 1977-05-10 Process for the preparation of an antibiotic derivative
CH582277A CH628022A5 (en) 1977-05-10 1977-05-10 Process for the preparation of an antibiotic derivative
CH582277 1977-05-10
CH582377 1977-05-10
CH745777 1977-06-17
CH745777A CH632010A5 (en) 1977-06-17 1977-06-17 Process for the preparation of a novel antibiotic

Publications (3)

Publication Number Publication Date
DK188778A DK188778A (da) 1978-11-11
DK148751B true DK148751B (da) 1985-09-16
DK148751C DK148751C (da) 1986-02-24

Family

ID=27175344

Family Applications (1)

Application Number Title Priority Date Filing Date
DK188778A DK148751C (da) 1977-05-10 1978-05-01 Fremgangsmaade til fremstilling af cyclosporinderivater

Country Status (17)

Country Link
US (2) US4220641A (da)
JP (1) JPS53139789A (da)
AU (1) AU526582B2 (da)
CA (1) CA1117046A (da)
DE (1) DE2819094A1 (da)
DK (1) DK148751C (da)
ES (1) ES469567A1 (da)
FI (1) FI59814C (da)
FR (1) FR2390420A1 (da)
GB (1) GB1591934A (da)
IE (1) IE46883B1 (da)
IL (1) IL54666A (da)
IT (1) IT1104195B (da)
NL (1) NL7804846A (da)
PH (1) PH13973A (da)
PT (1) PT68013B (da)
SE (3) SE438860B (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
SE448386B (sv) * 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
ATE43335T1 (de) * 1980-02-14 1989-06-15 Sandoz Ag Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung.
US4396542A (en) * 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
DE3260468D1 (en) * 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
EP0365044A3 (en) * 1984-08-02 1990-08-22 Sandoz Ag Novel pharmaceutical use of (nva)2-cyclosporine
GB8422253D0 (en) * 1984-09-04 1984-10-10 Sandoz Ltd Organic compounds
DE3587505T2 (de) 1984-10-04 1994-01-05 Sandoz Ag Monoklonale antikörper gegen zyklosporine.
US4727035A (en) * 1984-11-14 1988-02-23 Mahoney Walter C Immunoassay for cyclosporin
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
US5427960A (en) * 1987-03-27 1995-06-27 Abbott Laboratories Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
US5239057A (en) * 1987-03-27 1993-08-24 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
DE3851268T2 (de) * 1987-06-19 1995-01-26 Sandoz Ag Zyklische Peptolide.
EP0373260B1 (en) * 1987-06-22 1994-03-09 Merck & Co. Inc. Cyclosporin derivatives with modified "8-amino acid"
GB8717300D0 (en) * 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
US5227467A (en) * 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
DE3851152T2 (de) * 1987-09-03 1995-01-26 Univ Georgia Cyclosporin-augenmittel.
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4914188A (en) * 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
HU201577B (en) * 1988-12-20 1990-11-28 Gyogyszerkutato Intezet Process for producing cyclosporin antibiotics
US7081445B2 (en) * 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
GB8916901D0 (en) 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
EP0473961B1 (en) * 1990-08-15 1996-01-03 Abbott Laboratories Immunoassay reagents and method for determining cyclosporine
ATE158022T1 (de) * 1991-01-25 1997-09-15 Fujisawa Pharmaceutical Co Prozess zur produktion von cyclosporin-a und/oder c
ES2078374T3 (es) * 1991-04-06 1995-12-16 Dresden Arzneimittel Procedimiento para la produccion por fermentacion y aislamiento de ciclosporina a, y nuevas cepas formadoras de ciclosporina.
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
EP0725076B1 (en) * 1995-02-01 2001-06-06 National Research Development Corporation of India A process for the preparation of cyclosporin A from tolypocladium species
CN1079837C (zh) * 1995-02-28 2002-02-27 国家研究发展公司 从分枝层壁菌制备环胞多肽a的方法
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5747330A (en) * 1996-06-05 1998-05-05 Poli Industria Chimica Antibiotic producing microbe
DE29824679U1 (de) 1997-01-30 2002-03-28 Novartis Ag, Basel Pharmazeutische Zusammensetzungen
IN188719B (da) * 1997-09-08 2002-11-02 Panacea Biotec Ltd
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
KR100585348B1 (ko) 1997-10-08 2006-06-01 이소테크니카 인코포레이티드 중수소화된 시클로스포린 유사체 및 면역조절제로서 그의용도
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
JP4350898B2 (ja) 1998-07-01 2009-10-21 デビオファーム・ソシエテ・アノニム 活性の特徴が改善された新規のシクロスポリン
NZ531944A (en) * 2001-10-19 2006-03-31 Isotechnika Inc Synthesis of cyclosporin analogs
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
EP1809656A4 (en) 2004-09-29 2009-03-25 Amr Technology Inc CYCLOSPORINAL KINANALOGA AND ITS PHARMACEUTICAL APPLICATIONS
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2008036244A1 (en) * 2006-09-18 2008-03-27 The Burham Institute For Medical Research Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
NZ594755A (en) * 2009-01-30 2013-12-20 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) * 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) * 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
HUE042490T2 (hu) 2010-12-15 2019-07-29 Contravir Pharmaceuticals Inc 1-es és 3-as aminosav-pozícióban módosított ciklosporin analóg molekulák
CA2852056C (en) 2011-03-11 2021-08-10 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
WO2012145427A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
CA2921961A1 (en) 2013-08-26 2015-03-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4838877B1 (da) * 1970-06-30 1973-11-20 Toyo Jozo Kk
CH614931A5 (da) * 1975-11-04 1979-12-28 Sandoz Ag
US4215199A (en) * 1978-06-05 1980-07-29 Sandoz Ltd. Antibiotic production

Also Published As

Publication number Publication date
IL54666A0 (en) 1978-07-31
US4220641A (en) 1980-09-02
SE7805055L (sv) 1978-11-11
IT7849208A0 (it) 1978-05-05
PT68013A (fr) 1978-06-01
ES469567A1 (es) 1980-01-01
DK148751C (da) 1986-02-24
DK188778A (da) 1978-11-11
PT68013B (fr) 1980-03-05
IE46883B1 (en) 1983-10-19
FI59814C (fi) 1981-10-12
SE8401134D0 (sv) 1984-03-01
JPS6252760B2 (da) 1987-11-06
CA1117046A (en) 1982-01-26
JPS53139789A (en) 1978-12-06
IL54666A (en) 1980-12-31
FR2390420B1 (da) 1980-10-31
AU526582B2 (en) 1983-01-20
FI59814B (fi) 1981-06-30
PH13973A (en) 1980-11-20
AU3594778A (en) 1979-11-15
SE8401135D0 (sv) 1984-03-01
SE8401135L (sv) 1984-03-01
FR2390420A1 (fr) 1978-12-08
GB1591934A (en) 1981-07-01
SE8401134L (sv) 1984-03-01
DE2819094C2 (da) 1988-11-03
US4289851A (en) 1981-09-15
FI781348A (fi) 1978-11-11
SE438860B (sv) 1985-05-13
NL7804846A (nl) 1978-11-14
IE780932L (en) 1978-11-10
DE2819094A1 (de) 1978-11-23
IT1104195B (it) 1985-10-21

Similar Documents

Publication Publication Date Title
DK148751B (da) Fremgangsmaade til fremstilling af cyclosporinderivater
DK148752B (da) Fremgangsmaade til fremstilling af cyclosporinderivater
FI60701C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbar dihydrocyklosporin c
EP0109047B1 (en) Total synthesis of antitumor antibiotics
US5389639A (en) Amino alkanoic esters of rapamycin
Yamagishi et al. Antitumor agents, 110, Bryophyllin B, a novel potent cytotoxic bufadienolide from Bryophyllum pinnatum
US5385909A (en) Heterocyclic esters of rapamycin
US5221670A (en) Rapamycin esters
US5922730A (en) Alkylated rapamycin derivatives
US5457194A (en) Substituted aliphatic amine-containing macrocyclic immunomodulators
EP0549727A1 (en) Carboxylic acid esters of rapamycin
EP0011276A1 (en) Maytansinoids, their production and use
DK162647B (da) Fremgangsmaade til fremstilling af pyrido-imidazorifamyciner
JP2008532991A (ja) ラパマイシンの39−デスメトキシ誘導体
JPH04211699A (ja) 8位に変性アミノ酸を有する新規な免疫抑制シクロスポリン類縁体
HUT70207A (en) 21-norrapamycin, pharmaceutical compositions containing it and process for preparing them
US5541189A (en) Substituted aliphatic amine-containing macrocyclic immunomodulators
CA2266039A1 (en) Alkylated rapamycin derivatives
NO128710B (da)
US5530119A (en) Substituted alicyclic amine-containing macrocyclic immunomodulators
EP0855398B1 (en) Sesquiterpene derivatives having antiviral activity
US4226856A (en) Preparation and use of bouvardin and deoxybouvardin
US3944582A (en) Carbamates of ergolines
US5530120A (en) Substituted alicyclic aliphatic-amine containing macrocyclic immunomodulators
US4251529A (en) Ergot peptide alkaloids

Legal Events

Date Code Title Description
PBP Patent lapsed